SRR934932
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- overall_survival_months
- 36.859395532194476
- age_years
- 62
- sex
- Female
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.648
- IL6_JAK_STAT3_SIGNALING+0.620
- ANGIOGENESIS+0.607
- TNFA_SIGNALING_VIA_NFKB+0.586
- INTERFERON_GAMMA_RESPONSE+0.554
- ALLOGRAFT_REJECTION+0.544
- INTERFERON_ALPHA_RESPONSE+0.523
- E2F_TARGETS+0.513
- INFLAMMATORY_RESPONSE+0.491
- G2M_CHECKPOINT+0.476
Top 10 suppressed
- KRAS_SIGNALING_DN-0.422
- PANCREAS_BETA_CELLS-0.334
- BILE_ACID_METABOLISM-0.261
- SPERMATOGENESIS-0.261
- HEDGEHOG_SIGNALING-0.175
- XENOBIOTIC_METABOLISM-0.043
- MYOGENESIS-0.039
- HEME_METABOLISM-0.015
- APICAL_SURFACE-0.012
- PEROXISOME+0.039
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | 113D7756-712E-4EB4-9993-BBAF3C41AFEF | — | — | 0.982 |
| 2 | SRR934903 | — | — | 0.977 |
| 3 | SRR934926 | — | — | 0.977 |
| 4 | E9FC1686-028B-476C-B51B-4956213D874B | — | — | 0.973 |
| 5 | SRR934913 | — | — | 0.970 |
| 6 | C9EE359E-2F42-4D20-880D-FBF8B4953731 | — | — | 0.968 |
| 7 | SRR934875 | — | — | 0.968 |
| 8 | SRR934934 | — | — | 0.968 |
| 9 | SRR934965 | — | — | 0.967 |
| 10 | SRR934747 | — | — | 0.967 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 41 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.648 | Inavolisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.620 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.607 | Remibrutinib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.586 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.554 | Idelalisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.544 | Idelalisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.523 | Inavolisib | — uncovered |
| E2F_TARGETS | 0.513 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.491 | Idelalisib | — uncovered |
| G2M_CHECKPOINT | 0.476 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.473 | Inavolisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.456 | Idelalisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.452 | Idelalisib | — uncovered |
| APOPTOSIS | 0.425 | Idelalisib | — uncovered |
| COAGULATION | 0.420 | Binimetinib | — uncovered |
| MTORC1_SIGNALING | 0.420 | Inavolisib | — uncovered |
| COMPLEMENT | 0.407 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.407 | Inavolisib | — uncovered |
| HYPOXIA | 0.389 | Idelalisib | — uncovered |
| PROTEIN_SECRETION | 0.389 | Remibrutinib | — uncovered |